ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 619,49
1,87%
Dow Jones
39 118,86
-0,12%
DAX
18 334,24
0,55%
Brent Oil
85,515
0,48%
Bitcoin
63 018,15
0,67%
Registration Strip Icon for monitor Surveillez plusieurs cotations en temps réel des principales bourses, telles que Euronext Paris, NASDAQ, NYSE, AMEX, Bovespa et plus encore.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. argenx SE (ARGX)

  7. argenx SE (ARGX) Actualités

ARGX

argenx (ARGX)

argenx SE
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:ARGX
DateHeureSourceTitreSymboleSociété
25/06/202422h30GlobeNewswire Inc.argenx Highlights Breadth of Autoimmune Pipeline with New Multifocal Motor Neuropathy Data at 2024 Peripheral Nerve Society Annual MeetingNASDAQ:ARGXargenx SE
21/06/202422h50GlobeNewswire Inc.argenx Announces FDA Approval of VYVGART Hytrulo for Chronic Inflammatory Demyelinating PolyneuropathyNASDAQ:ARGXargenx SE
17/06/202412h05Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:ARGXargenx SE
17/06/202407h00GlobeNewswire Inc.argenx to unveil its ‘Vision 2030: Taking Breakthrough Science to 50,000 Patients’ during its Upcoming R&D Day on July 16, 2024NASDAQ:ARGXargenx SE
04/06/202407h00GlobeNewswire Inc.argenx to Present at Goldman Sachs 45th Annual Global Healthcare ConferenceNASDAQ:ARGXargenx SE
09/05/202407h00GlobeNewswire Inc.argenx Reports First Quarter 2024 Financial Results and Provides Business UpdateNASDAQ:ARGXargenx SE
07/05/202423h30GlobeNewswire Inc.argenx announces results of Annual General Meeting of ShareholdersNASDAQ:ARGXargenx SE
07/05/202407h00GlobeNewswire Inc.argenx to Present at BofA Securities 2024 Health Care ConferenceNASDAQ:ARGXargenx SE
02/05/202407h00GlobeNewswire Inc.argenx to Report First Quarter 2024 Financial Results and Business Update on May 9, 2024NASDAQ:ARGXargenx SE
16/04/202407h00GlobeNewswire Inc.argenx Data Highlight Evidence that VYVGART and VYVGART Hytrulo Drive Transformative Outcomes for Patients with Debilitating Autoimmune DiseaseNASDAQ:ARGXargenx SE
27/03/202407h00GlobeNewswire Inc.argenx Advances Clinical Development of Efgartigimod in Primary Sjogren’s DiseaseNASDAQ:ARGXargenx SE
26/03/202421h00GlobeNewswire Inc.argenx Announces Annual General Meeting of Shareholders on May 7, 2024NASDAQ:ARGXargenx SE
26/03/202407h00GlobeNewswire Inc.argenx Announces Approval of VYVGART (efgartigimod alfa) in Japan for Adults with Primary Immune ThrombocytopeniaNASDAQ:ARGXargenx SE
07/03/202422h01GlobeNewswire Inc.argenx Delivers on Promise to Transform Patient Expectations in Autoimmunity at American Academy of Neurology 2024 Annual MeetingNASDAQ:ARGXargenx SE
29/02/202407h00GlobeNewswire Inc.argenx Reports Full Year 2023 Financial Results and Provides Fourth Quarter Business UpdateNASDAQ:ARGXargenx SE
26/02/202407h00GlobeNewswire Inc.argenx to Present at Upcoming Investor ConferencesNASDAQ:ARGXargenx SE
22/02/202407h00GlobeNewswire Inc.argenx to Report Full Year 2023 Financial Results and Fourth Quarter Business Update on February 29, 2024NASDAQ:ARGXargenx SE
20/02/202407h00GlobeNewswire Inc.argenx Announces FDA Acceptance of Supplemental Biologics License Application with Priority Review for VYVGART Hytrulo in Chronic Inflammatory Demyelinating PolyneuropathyNASDAQ:ARGXargenx SE
18/01/202407h00GlobeNewswire Inc.argenx Announces Approval of VYVDURA® (efgartigimod alfa and hyaluronidase-qvfc) Injection for Subcutaneous Use in Japan for Generalized Myasthenia GravisNASDAQ:ARGXargenx SE
08/01/202407h00GlobeNewswire Inc.argenx Highlights 2024 Strategic PrioritiesNASDAQ:ARGXargenx SE
02/01/202407h00GlobeNewswire Inc.argenx to Present at 42nd Annual J.P. Morgan Healthcare ConferenceNASDAQ:ARGXargenx SE
20/12/202318h37Dow Jones NewsArgenx Down Nearly 26%, on Pace for Record Percent Decrease -- Data TalkNASDAQ:ARGXargenx SE
20/12/202307h00GlobeNewswire Inc.argenx Reports Topline Results from ADDRESS Study of Efgartigimod SC in PemphigusNASDAQ:ARGXargenx SE
28/11/202317h16Dow Jones NewsArgenx Down Over 10%, On Track for Largest Percent Decrease Since May 2022 -- Data TalkNASDAQ:ARGXargenx SE
28/11/202313h03Dow Jones NewsArgenx Shares Down After Vyvgart Study Misses Primary EndpointNASDAQ:ARGXargenx SE
28/11/202307h00GlobeNewswire Inc.argenx Reports Topline Results from ADVANCE-SC Study of VYVGART Hytrulo in Primary Immune ThrombocytopeniaNASDAQ:ARGXargenx SE
16/11/202313h40GlobeNewswire Inc.argenx Announces European Commission Approval of Subcutaneous VYVGART® (efgartigimod alfa) for Generalized Myasthenia GravisNASDAQ:ARGXargenx SE
01/11/202307h00GlobeNewswire Inc.argenx Highlights Data Evaluating VYVGART in Neuromuscular Autoimmune Disease at AANEM and MGFA Scientific SessionsNASDAQ:ARGXargenx SE
31/10/202307h00GlobeNewswire Inc.argenx Reports Third Quarter 2023 Financial Results and Provides Business UpdateNASDAQ:ARGXargenx SE
24/10/202307h00GlobeNewswire Inc.argenx to Report Third Quarter 2023 Financial Results and Business Update on October 31, 2023NASDAQ:ARGXargenx SE
 Showing the most relevant articles for your search:NASDAQ:ARGX

Dernières Valeurs Consultées

NYSE
DIS
Walt Disney
EU
VK
Vallourec
EU
BEL20
Bel 20
NASDAQ
NVDA
NVIDIA
EU
PX1
CAC 40
NASDAQ
AMZN
Amazon.com
SPI
SP500
S&P 500
EU
CAP
Capgemini
EU
EN
Bouygues
NASDAQ
GOOGL
Alphabet
COIN
ETHUSD
Ethereum
NYSE
NKE
Nike
USI
USTECH100
US Tech 100
NYSE
JPM
JP Morgan Chase
EU
AF
Air FranceKLM
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés